Cargando…

A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia

Although severe cases and mortality of coronavirus disease 2019 (COVID-19) are proportionally infrequent, these cases are strongly linked to patients with conditions of metabolic syndrome (obesity, hypertension, diabetes, and dyslipidemia). However, the pathophysiology of COVID-19 in relation to met...

Descripción completa

Detalles Bibliográficos
Autores principales: Makhoul, Elias, Aklinski, Joseph L, Miller, Jesse, Leonard, Cara, Backer, Sean, Kahar, Payal, Parmar, Mayur S, Khanna, Deepesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420458/
https://www.ncbi.nlm.nih.gov/pubmed/36051728
http://dx.doi.org/10.7759/cureus.27438
_version_ 1784777394604736512
author Makhoul, Elias
Aklinski, Joseph L
Miller, Jesse
Leonard, Cara
Backer, Sean
Kahar, Payal
Parmar, Mayur S
Khanna, Deepesh
author_facet Makhoul, Elias
Aklinski, Joseph L
Miller, Jesse
Leonard, Cara
Backer, Sean
Kahar, Payal
Parmar, Mayur S
Khanna, Deepesh
author_sort Makhoul, Elias
collection PubMed
description Although severe cases and mortality of coronavirus disease 2019 (COVID-19) are proportionally infrequent, these cases are strongly linked to patients with conditions of metabolic syndrome (obesity, hypertension, diabetes, and dyslipidemia). However, the pathophysiology of COVID-19 in relation to metabolic syndrome is not well understood. Thus, the goal of this secondary literature review was to examine the relationship between severe acute respiratory syndrome (SARS-CoV-2) infection and the individual conditions of metabolic syndrome. The objective of this secondary literature review was achieved by examining primary studies, case studies, and other secondary studies, to obtain a comprehensive perspective of theories and observations of COVID-19 etiology with metabolic syndrome. The most extensive research was available on the topics of diabetes, hypertension, and obesity, which yielded multiple (and sometimes conflicting) hypothetical pathophysiology. The sources on dyslipidemia and COVID-19 were scarcer and failed to provide an equally comprehensive image, highlighting the need for further research. It was concluded that hypertension had the strongest correlation with COVID-19 incidence (followed by obesity), yet the causative pathophysiology was ambiguous; most likely related to cardiovascular, angiotensin-converting enzyme 2 (ACE-2)-related complications from renin-angiotensin-aldosterone system (RAAS) imbalance. Obesity was also positively correlated to the severity of COVID-19 cases and was believed to contribute to mechanical difficulties with respiration, in addition to hypothetical connections with the expression of ACE-2 on abundant adipose tissue. Diabetes was believed to contribute to COVID-19 severity by producing a chronic inflammatory state and interfering with neutrophil and T-cell function. Furthermore, there were indications that COVID-19 may induce acute-onset diabetes and diabetic ketoacidosis. Lastly, dyslipidemia was concluded to potentially facilitate SARS-CoV-2 infection by enhancing lipid rafts and immunosuppressive functions. There were also indications that cholesterol levels may have prognostic indications and that statins may have therapeutic benefits.
format Online
Article
Text
id pubmed-9420458
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-94204582022-08-31 A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia Makhoul, Elias Aklinski, Joseph L Miller, Jesse Leonard, Cara Backer, Sean Kahar, Payal Parmar, Mayur S Khanna, Deepesh Cureus Endocrinology/Diabetes/Metabolism Although severe cases and mortality of coronavirus disease 2019 (COVID-19) are proportionally infrequent, these cases are strongly linked to patients with conditions of metabolic syndrome (obesity, hypertension, diabetes, and dyslipidemia). However, the pathophysiology of COVID-19 in relation to metabolic syndrome is not well understood. Thus, the goal of this secondary literature review was to examine the relationship between severe acute respiratory syndrome (SARS-CoV-2) infection and the individual conditions of metabolic syndrome. The objective of this secondary literature review was achieved by examining primary studies, case studies, and other secondary studies, to obtain a comprehensive perspective of theories and observations of COVID-19 etiology with metabolic syndrome. The most extensive research was available on the topics of diabetes, hypertension, and obesity, which yielded multiple (and sometimes conflicting) hypothetical pathophysiology. The sources on dyslipidemia and COVID-19 were scarcer and failed to provide an equally comprehensive image, highlighting the need for further research. It was concluded that hypertension had the strongest correlation with COVID-19 incidence (followed by obesity), yet the causative pathophysiology was ambiguous; most likely related to cardiovascular, angiotensin-converting enzyme 2 (ACE-2)-related complications from renin-angiotensin-aldosterone system (RAAS) imbalance. Obesity was also positively correlated to the severity of COVID-19 cases and was believed to contribute to mechanical difficulties with respiration, in addition to hypothetical connections with the expression of ACE-2 on abundant adipose tissue. Diabetes was believed to contribute to COVID-19 severity by producing a chronic inflammatory state and interfering with neutrophil and T-cell function. Furthermore, there were indications that COVID-19 may induce acute-onset diabetes and diabetic ketoacidosis. Lastly, dyslipidemia was concluded to potentially facilitate SARS-CoV-2 infection by enhancing lipid rafts and immunosuppressive functions. There were also indications that cholesterol levels may have prognostic indications and that statins may have therapeutic benefits. Cureus 2022-07-29 /pmc/articles/PMC9420458/ /pubmed/36051728 http://dx.doi.org/10.7759/cureus.27438 Text en Copyright © 2022, Makhoul et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Makhoul, Elias
Aklinski, Joseph L
Miller, Jesse
Leonard, Cara
Backer, Sean
Kahar, Payal
Parmar, Mayur S
Khanna, Deepesh
A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia
title A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia
title_full A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia
title_fullStr A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia
title_full_unstemmed A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia
title_short A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia
title_sort review of covid-19 in relation to metabolic syndrome: obesity, hypertension, diabetes, and dyslipidemia
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420458/
https://www.ncbi.nlm.nih.gov/pubmed/36051728
http://dx.doi.org/10.7759/cureus.27438
work_keys_str_mv AT makhoulelias areviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT aklinskijosephl areviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT millerjesse areviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT leonardcara areviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT backersean areviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT kaharpayal areviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT parmarmayurs areviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT khannadeepesh areviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT makhoulelias reviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT aklinskijosephl reviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT millerjesse reviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT leonardcara reviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT backersean reviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT kaharpayal reviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT parmarmayurs reviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia
AT khannadeepesh reviewofcovid19inrelationtometabolicsyndromeobesityhypertensiondiabetesanddyslipidemia